Featured Press Releases

enGene’s Detalimogene Receives RMAT Designation from the FDA, Opening the Path for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

enGene’s Detalimogene Receives RMAT Designation from the FDA, Opening the Path for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

Marius Pharmaceuticals and Hims & Hers™ collaborate to expand access to KYZATREX® (testosterone undecanoate) CIII capsules, the first FDA-approved oral testosterone therapy available on the Hims & Hers platform

Marius Pharmaceuticals and Hims & Hers™ collaborate to expand access to KYZATREX® (testosterone undecanoate) CIII capsules, the first FDA-approved oral testosterone therapy available on the Hims & Hers platform

  • 11 Sep 2025

Marius Pharmaceuticals, Inc.  announced a collaboration with Hims & Hers™, one of the largest...

Hanmi Pharmaceutical Launches

Hanmi Pharmaceutical Launches 'Aditams' in Mexico, Expanding into Latin America

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer's Treatment

Merz Aesthetics® Introduces New BELOTERO® Syringe, Offering Greater Precision, Comfort, and Ease of Use.

Merz Aesthetics® Introduces New BELOTERO® Syringe, Offering Greater Precision, Comfort, and Ease of Use.

Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

ProductLife Group Appoints Dr. James Burt as CEO

ProductLife Group Appoints Dr. James Burt as CEO

  • ProductLife Group
  • 24 Mar 2026
Constance Sabbagh Appointed as General Manager as Avanzanite Expands French Operations

Constance Sabbagh Appointed as General Manager as Avanzanite Expands French Operations

  • Avanzanite Bioscience B.V.
  • 24 Mar 2026
Emerging From Stealth, Oryon Cell Therapies Targets Autologous Neuron Replacement for Parkinson’s Disease and Neurodegenerative Disorders

Emerging From Stealth, Oryon Cell Therapies Targets Autologous Neuron Replacement for Parkinson’s Disease and Neurodegenerative Disorders

  • Oryon Cell Therapies
  • 23 Mar 2026
Samsung Biologics Labor Union Warns of

Samsung Biologics Labor Union Warns of "Structural Supply Chain Risk" Amid Labor Dispute, Citing Systemic Governance Failures

  • Samsung Biologics Labor Union
  • 23 Mar 2026
Convergent Therapeutics Appoints Michael Rossi to Board

Convergent Therapeutics Appoints Michael Rossi to Board

  • Convergent Therapeutics Inc.
  • 20 Mar 2026
Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

  • Johnson & Johnson
  • 06 Mar 2026
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular
March   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.